Skip to content
  • Sunday, 26 July 2026
  • 2:59 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • EHA26: J&J’s multiple myeloma therapies impress with new data – Pharmaceutical Technology
Pharmaceutical R&D

EHA26: J&J’s multiple myeloma therapies impress with new data – Pharmaceutical Technology

Teuku Ryan Jun 16, 2026 0

The European Hematology Association (EHA) 2026 conference, held from June 11th to 14th in Stockholm, Sweden, served as a pivotal…

Read More
Pharmaceutical R&D

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology

Teuku Ryan Jun 2, 2026 0

The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…

Read More
Pharmaceutical R&D

Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape

Teuku Ryan Apr 25, 2026 0

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…

Read More
Pharmaceutical R&D

Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care

Teuku Ryan Mar 28, 2026 0

Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…

Read More
Ultraheavy Atomic Nuclei May Solve the Longstanding Mystery of Ultrahigh Energy Cosmic Rays and the Amaterasu ParticleAncient Chinese Exercise Practice Baduanjin Found as Effective as Brisk Walking in Reducing Blood Pressure According to New Clinical TrialAstrocytes and Tanycytes Emerge as Critical Regulators of Appetite in Groundbreaking Hypothalamic ResearchThe Alarming Rise of AI Chatbots in Youth Mental Healthcare: A Silent Epidemic
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ